On May 26, WuXi XDC (02268.HK) fell 3.14% in regular trading, trading at 56.7 HKD/share, with trading volume of 70.50 million HKD.
Within the Life Sciences Tools & Services sector where WuXi XDC belongs, individual stock performance was mixed. Among sector peers, WuXi Biologics up 5.01%, GenScript Biotech up 0.31%, WuXi AppTec down 1.31%, XtalPi down 2.01%, Insilico Medicine down 3.13%.
WuXi XDC is a leading investment holding company primarily engaged in providing comprehensive contract research, development, and manufacturing organization (CRDMO) services for antibody-drug conjugates (ADCs) and other bioconjugate drugs, with operations spanning the domestic market, North America, Europe, and other regions worldwide.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments